Epigenetic Markers For Development of Schizophrenia

精神分裂症发展的表观遗传标记

• 批准号: 8720065
• 负责人: ALESSANDRO GUIDOTTI
• 金额: $ 19.74万
• 依托单位: UNIVERSITY OF ILLINOIS AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-08-12 至 2016-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8720065
• 关键词: Acids; Addendum; Affect; Appearance; Autistic Disorder; Base Excision Repairs; Binding; Binding Proteins; Biochemical; Biological Markers; Bipolar Disorder; Brain; Brain-Derived Neurotrophic Factor; California; Candidate Disease Gene; China; Chinese People; Chromatin; Chronic Schizophrenia; Cytidine Deaminase; Cytosine; DNA; DNA Damage; DNA Methylation; DNA Methyltransferase; DNA Modification Methylases; DSM-IV; Data; Deaminase; Development; Disease; Early Intervention; Enzymes; Epigenetic Process; Figs - dietary; Functional disorder; GADD45; GADD45 protein; Genes; Genetic; Genetic Transcription; Glucocorticoid Receptor; Goals; Health; Illinois; Individual; Island; Lymphocyte; Measures; Messenger RNA; Methylation; Mitotic; Mixed Function Oxygenases; Molecular Conformation; Multicenter Studies; Neurons; Pathology; Pathway interactions; Patients; Process; Promoter Regions; Protein translocation; Proteins; Psychotic Disorders; Receptor Gene; Recruitment Activity; Research; Research Personnel; Research Support; Role; Schizophrenia; Symptoms; Thymidine; Universities; cohort; demethylation; epigenetic marker; first episode schizophrenia; follow-up; gamma-Aminobutyric Acid; high risk; mRNA Expression; meetings; neuropsychiatry; outcome forecast; promoter; psychotic symptoms; public health relevance; repair enzyme

DESCRIPTION (provided by applicant): The goal of this proposed research is to determine whether differences in the expression of epigenetic related biomarkers are present in lymphocytes of people with genetic high risk and/or prodromal symptoms of schizophrenia (HRSK subjects) as previously found in lymphocytes of chronic schizophrenia (SZ) patients. We will also assess whether the presence of these biomarkers predicts which HRSK subjects will progressively develop more psychotic symptoms over a two year period and who will convert from HRSK status to first episode schizophrenia or another diagnosable psychotic disorder. Investigators on this proposal, have been collaborating with a group of investigators in Hunan, China for several years (Wu et al., 2008; 2012). The China group is currently conducting a multi-center study supported by the Chinese Ministry of Health that involves 5000 HRSK and 2000 control subjects. The research we are proposing would be an addendum to this larger study. DNA methylation and demethylation are key epigenetic components involved in orchestrating transcription of specific genes in post mitotic neurons (Guidotti et al., 2011). It has been suggested that the DNA methylation/demethylation process is perturbed in neuropsychiatric disorders such as schizophrenia (SZ), bipolar disorder (BP), and autism. We have shown that abnormalities in some of these epigenetic marks in the brain of SZ patients are also present in their lymphocytes. Lymphocytes of SZ patients have higher DNMT1 mRNA expression than non-psychotic controls (Zhubi et al 2009), higher levels of other methylating and demethylating enzymes (growth arrest and DNA damage-inducible protein [GADD45] and ten-eleven translocation protein [TET]), and lower levels of glucocorticoid receptor and GAD67 mRNA (preliminary data). If differences in these potential epigenetic biomarkers can be confirmed in lymphocytes of HRSK subjects, some of the underlying biochemical developmental pathology leading to SZ might be uncovered. This result could provide epigenetic biomarkers useful in predicting which HRSK subjects are more likely to develop full symptoms of SZ or a related psychosis. Identifying potential biomarkers would have implications for prognosis and identifying patients who would be most likely to benefit from intensive early intervention and specialized treatment. This background leads us to pursue three Specific Aims for the current proposed study: AIM1: Measure the expression level of DNA methylation related genes in lymphocytes of HRSK subjects at baseline compared to controls and first episode and chronic SZ patients. AIM 2: Determine whether epigenetic chromatin status and the expression of SZ candidate genes is regulated by the binding of proteins that are constituents of the DNA- methylation/demethylation pathways in lymphocytes of HRSK subjects at baseline compared to controls and first episode and chronic SZ patients. AIM 3 Determine whether HRSK subjects who also have epigenetic lymphocyte abnormalities at baseline are more likely to progress to more severe psychotic-like symptoms or convert to diagnosable psychotic status during a two year follow up. This proposed research is potentially a major step toward the identification of objective biomarkers capable of predicting conversion to psychosis in HRSK subjects.

描述(申请人提供)：这项拟议研究的目标是确定表观遗传相关生物标记物的表达是否存在于具有遗传高危和/或精神分裂症前驱症状的人(HRSK受试者)的淋巴细胞中，就像以前在慢性精神分裂症(SZ)患者的淋巴细胞中发现的那样。我们还将评估这些生物标志物的存在是否可以预测哪些HRSK受试者在两年内会逐渐发展为更多的精神病症状，以及谁会从HRSK状态转变为首发精神分裂症或其他可诊断的精神障碍。关于这一提议的调查人员与湖南的一组调查人员中国合作了几年(吴等人，2008年；2012年)。中国小组目前正在进行一项由中国卫生部支持的多中心研究，涉及5000名HRSK和2000名对照对象。我们提议的研究将是这项更大规模研究的补充。DNA甲基化和去甲基化是参与有丝分裂后神经元中特定基因转录的关键表观遗传学成分(Guidotti等人，2011年)。已有研究表明，DNA甲基化/去甲基化过程在精神分裂症(SZ)、双相情感障碍(BP)和自闭症等神经精神障碍中受到干扰。我们已经证明，SZ患者大脑中的一些表观遗传标记的异常也存在于他们的淋巴细胞中。与非精神病对照组相比，SZ患者的淋巴细胞DNMT1mRNA表达水平更高(朱比等人，2009)，其他甲基化和去甲基化酶(生长停滞和DNA损伤诱导蛋白[GADD45]和Tet-11易位蛋白[Tet])水平更高，糖皮质激素受体和GAD67 mRNA水平更低(初步数据)。如果这些潜在的表观遗传生物标记物的差异能够在HRSK受试者的淋巴细胞中得到证实，那么导致SZ的一些潜在的生化发育病理可能被揭示。这一结果可以提供表观遗传生物标记物，用于预测哪些HRSK受试者更有可能发展为SZ或相关精神病的全部症状。确定潜在的生物标志物将对预后有影响，并确定最有可能从强化早期干预和专门治疗中受益的患者。在此背景下，本研究提出了三个具体的研究目标：AIM1：检测基线时HRSK受试者淋巴细胞DNA甲基化相关基因的表达水平，并与对照组、首发和慢性SZ患者进行比较。目的：与对照组、首发和慢性SZ患者比较，研究基线状态下HRSK受试者外周血淋巴细胞染色质状态和SZ候选基因的表达是否受DNA甲基化/去甲基化途径组成的蛋白质结合的调节。目的3确定HRSK受试者在两年的随访中，同时存在表观遗传淋巴细胞异常的患者是否更有可能进展为更严重的精神病样症状或转变为可诊断的精神状态。这项拟议的研究可能是朝着识别能够预测HRSK受试者向精神病转化的客观生物标志物迈出的重要一步。